Increasing the levels of TTP to enable the mRNA-destabilizing activity of this RNA binding protein—for example, through the use of inhibitors of anti-TTP miRNAs [24]—is an attractive therapeutic possibility in cancers [24], atherosclerosis [51], and perhaps other conditions. Here, ZFP36 is linked to cancer.